


Application No. 09/743,781  
Paper Dated January 27, 2004  
Reply to USPTO Correspondence of October 27, 2003  
Attorney Docket No. 4303-030806



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/743,781  
Applicant : Daniel Paris et al.  
Filed : March 28, 2001  
Title : MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY  
AS A THERAPEUTIC  
Group Art Unit : 1614  
Examiner : Cybille Delacroix-Muirheid  
Confirmation No. : 7516  
Customer No. : 28289

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Sir:

In response to the Office Action of October 27, 2003, please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** begin on page 3 of this paper.


As requested by the Examiner, submitted herewith is a new Declaration and Power of Attorney.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 27, 2004.

Helen Gerace

(Name of Person Mailing Paper)

*Helen Gerace* January 27, 2004  
Signature Date



## AMENDMENT TRANSMITTAL LETTER

Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
FEB 05 2004  
TECH CENTER 1600/2900

Application No.: 09/743,781 Filing Date: March 28, 2001  
Examiner: Cybill Delacroix-Muirheid Group Art Unit: 1614  
Invention: MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY AS A THERAPEUTIC

Transmitted herewith is an Amendment and Declaration and Power of Attorney in the above-identified application.

- ☒ Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.  
A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.  
☒ No additional fee is required.  
The fee has been calculated as shown below:


| No. of Claims<br>after<br>Amendment             | Highest No.<br>Previously<br>Paid For | Present<br>Extra |   | Small Entity<br>Rate | Non-Small<br>Entity Rate | Charge |
|---|---------------------------------------|------------------|---|----------------------|--------------------------|--------|
| Total <u>3</u>                                  | <u>21</u>                             | <u>-0-</u>       | x | \$ 9.00              | \$ 18.00                 | \$ -0- |
| Indep. <u>1</u>                                 | <u>5</u>                              | <u>-0-</u>       | x | \$ 43.00             | \$ 86.00                 | \$ -0- |
| First Presentation of Multiple Dependent Claims |                                       |                  |   | + \$145.00           | + \$290.00               | \$ -0- |
| TOTAL ADDITIONAL FEE                            |                                       |                  |   |                      |                          | \$ -0- |

- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication to Deposit Account No. 23-0650. Please refund any overpayment to Deposit Account No. 23-0650. An original and two copies of this sheet are enclosed.  
☒ Any additional filing fees required under 37 CFR 1.16.  
☒ Any patent application processing fees under 37 CFR 1.17.

January 27, 2004

Date

By



Gwen R. Acker Wood, Ph.D.

Registration No. 51,027

Attorney for Applicants

436 Koppers Building

436 Seventh Avenue

Pittsburgh, PA 15219-1818

Telephone: (412) 471-8815


Facsimile: (412) 471-4094

E-mail: [webblaw@webblaw.com](mailto:webblaw@webblaw.com)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 27, 2004.

Helen Gerace

(Name of Person Mailing Paper)



Signature

January 27, 2004

Date